cabozantinib

Drug identity checked against registry records

Also recorded as XL184

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPCNCT01995058ExelixisPhase 2Terminated2014-11Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.